ALNY Alnylam Pharmaceuticals Inc
Price (delayed)
$241.84
Market cap
$31.31B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.18
Enterprise value
$31.64B
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is
Highlights
The equity has soared by 130% YoY and by 107% from the previous quarter
ALNY's EPS is up by 38% year-on-year and by 16% since the previous quarter
The company's quick ratio fell by 9% YoY
Key stats
What are the main financial stats of ALNY
Market
Valuations
Earnings
Shares outstanding
129.46M
Market cap
$31.31B
Enterprise value
$31.64B
Price to earnings (P/E)
N/A
Price to book (P/B)
464.95
Price to sales (P/S)
13.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.07
Revenue
$2.25B
Gross profit
$1.92B
Operating income
-$176.89M
Net income
-$278.16M
EBIT
-$235.52M
EBITDA
-$178.85M
Free cash flow
-$42.59M
Per share
Balance sheet
Liquidity
EPS
-$2.18
EPS diluted
-$2.18
Free cash flow per share
-$0.33
Book value per share
$0.52
Revenue per share
$17.61
TBVPS
$33.22
Total assets
$4.24B
Total liabilities
$4.17B
Debt
$1.3B
Equity
$67.09M
Working capital
$2.11B
Debt to equity
19.32
Current ratio
2.78
Quick ratio
2.61
Net debt/EBITDA
-1.84
Margins
Efficiency
Dividend
EBITDA margin
-8%
Gross margin
85.6%
Net margin
-12.4%
Operating margin
-7.9%
Return on assets
-6.8%
Return on equity
N/A
Return on invested capital
-7.1%
Return on capital employed
-7.7%
Return on sales
-10.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALNY stock price
How has the Alnylam Pharmaceuticals stock price performed over time
Intraday
-0.24%
1 week
-2.53%
1 month
-8.7%
1 year
62.94%
YTD
2.78%
QTD
2.78%
Financial performance
How have Alnylam Pharmaceuticals's revenue and profit performed over time
Revenue
$2.25B
Gross profit
$1.92B
Operating income
-$176.89M
Net income
-$278.16M
Gross margin
85.6%
Net margin
-12.4%
The company's operating margin rose by 49% YoY and by 12% QoQ
The net margin has grown by 49% YoY and by 22% from the previous quarter
The company's net income rose by 37% YoY and by 16% QoQ
Alnylam Pharmaceuticals's operating income has increased by 37% YoY and by 6% QoQ
Growth
What is Alnylam Pharmaceuticals's growth rate over time
Valuation
What is Alnylam Pharmaceuticals stock price valuation
P/E
N/A
P/B
464.95
P/S
13.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.07
ALNY's EPS is up by 38% year-on-year and by 16% since the previous quarter
The equity has soared by 130% YoY and by 107% from the previous quarter
ALNY's price to sales (P/S) is 44% lower than its 5-year quarterly average of 24.6 but 4.2% higher than its last 4 quarters average of 13.2
The company's revenue rose by 23% YoY and by 7% QoQ
Efficiency
How efficient is Alnylam Pharmaceuticals business performance
The return on assets has increased by 44% year-on-year and by 19% since the previous quarter
ALNY's return on sales is up by 39% year-on-year but it is down by 18% since the previous quarter
ALNY's return on invested capital is down by 27% since the previous quarter but it is up by 25% year-on-year
Dividends
What is ALNY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALNY.
Financial health
How did Alnylam Pharmaceuticals financials performed over time
The total assets has increased by 11% YoY
Alnylam Pharmaceuticals's current ratio has decreased by 10% YoY
The equity has soared by 130% YoY and by 107% from the previous quarter
Alnylam Pharmaceuticals's debt to equity has plunged by 52% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.